Unlocking the potential of
genomic medicine

Overview



Aevi Genomic Medicine is focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering diseases.  More>>

There are no items to display.

Stock Quote

Recent News

More >>
Date Title and Summary
Toggle Summary08/29/2018
PHILADELPHIA , Aug. 29, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 5:05
Toggle Summary08/21/2018
- Initiation of enrollment in Part B of the ASCEND trial - Top-line data for Parts A and B of ASCEND expected in Q4 2018 PHILADELPHIA , Aug. 21, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced the sale of 5.1 million shares of its common stock for
Toggle Summary08/14/2018
- Top Line Data for Part A expected in Q4 2018 PHILADELPHIA , Aug. 14, 2018 /PRNewswire/   -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced that it has completed enrollment in Part A (n=64) of its Phase 2 ASCEND clinical trial, which is assessing a mGluR mutation positive

Recent Presentations

More >>
Date Title
09/05/2018
06/20/2018
06/07/2018
03/28/2018
03/16/2018

Upcoming Events

More >>
There are currently no events to display.

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Aevi Genomic Medicine, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Copyright Nasdaq. Minimum 15 minutes delayed.